Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
Business Wire (May 8, 2013)
-
Business Wire (May 1, 2013)
-
Business Wire (Apr 23, 2013)
-
Business Wire (Apr 9, 2013)
-
Business Wire (Apr 1, 2013)
-
Business Wire (Mar 14, 2013)
-
Business Wire (Mar 7, 2013)
-
Business Wire (Feb 27, 2013)
-
Business Wire (Feb 19, 2013)
-
Business Wire (Feb 7, 2013)
-
Business Wire (Jan 31, 2013)
To learn more about Seeking Alpha Pro, click here.
-
Post-ASCO Thoughts On ArquleChimera Research Group • Fri, Aug 3, 2012
-
ArQule Joins Forces with Daiichi Sankyo to Fight CancerEben Tessari • Tue, Nov 11, 2008
-
Arqule’s Theater of the AbsurdOhad Hammer • Tue, Nov 11, 2008
-
ArQule Could Gain Ahead of American Society of Clinical Oncology MeetingH.S. Ayoub • Mon, May 21, 2007
-
ArQule, Inc.: Millenco Boosts Stake to 6.3%Lon Juricic • Tue, Apr 24, 2007
-
ArQule Inc. Q1 2010 Earnings Call TranscriptThu, May 6, 2010
-
ArQule, Inc. Q3 2009 Earnings Call TranscriptThu, Nov 5, 2009
-
ArQule, Inc. Q4 2008 Earnings Call TranscriptThu, Mar 5, 2009
-
ArQule, Inc. Q3 2008 Earnings Call TranscriptMon, Nov 10, 2008
-
ArQule, Inc., Q2 2008 Earnings Call TranscriptMon, Aug 11, 2008
-
ArQule Inc. Q1 2008 Earnings Call TranscriptMon, May 12, 2008
-
Business Wire (May 8, 2013)
-
Business Wire (May 1, 2013)
-
Business Wire (Apr 23, 2013)
-
Business Wire (Apr 9, 2013)
-
Business Wire (Apr 1, 2013)
-
Business Wire (Mar 14, 2013)
-
Business Wire (Mar 7, 2013)
-
Business Wire (Feb 27, 2013)
-
Business Wire (Feb 19, 2013)
-
Business Wire (Feb 7, 2013)
-
Business Wire (Jan 31, 2013)
-
Business Wire (Dec 13, 2012)
-
Business Wire (Dec 5, 2012)
-
Business Wire (Nov 7, 2012)
-
Business Wire (Nov 1, 2012)
-
Business Wire (Oct 25, 2012)
-
at MarketWatch.com (Oct 3, 2012)
-
at MarketWatch.com (Oct 2, 2012)
ARQL vs. ETF Alternatives
Company Description
We are a clinical-stage biotechnology company engaged in the research and development of innovative cancer therapeutics. Our mission is to produce novel medicines with differentiated mechanisms of action that target the specific biological pathways implicated in a wide range of cancers. We... More









